Treatment options for influenza
Pro Research Analysisby 
Searched over 200M research papers
Antiviral Drug Treatment Options for Influenza
Antiviral drugs are a mainstay in the treatment of influenza, especially for those who are severely ill or at high risk of complications. The most commonly used antivirals are neuraminidase inhibitors, such as oseltamivir, zanamivir, peramivir, and laninamivir, which are effective against both influenza A and B viruses. Early administration of these drugs, ideally within 48 hours of symptom onset, is associated with reduced mortality and better outcomes, particularly in hospitalized and critically ill patients Falagas2010Palomba2021Fiore2011. Newer drugs, such as baloxavir marboxil (a cap-dependent endonuclease inhibitor) and favipiravir (an RNA polymerase inhibitor), have shown promising efficacy in clinical trials and are expanding the available treatment options Koszalka2022Odnovorov2020Singh2023+1 MORE.
Combination Therapy and Drug Resistance in Influenza Treatment
The rapid mutation and genetic variability of the influenza virus can lead to resistance against antiviral drugs, especially when monotherapy is used. Combination therapy, which involves using two or more antivirals with different mechanisms of action, is being explored as a strategy to improve treatment effectiveness and reduce the risk of resistance. Studies suggest that combining neuraminidase inhibitors with other classes of antivirals, such as polymerase inhibitors or immunomodulators, may offer added benefits, particularly for severe or complicated cases and immunocompromised patients Koszalka2022Batool2023Dunning2014. However, more clinical trials are needed to confirm the advantages and safety of these combinations Koszalka2022Dunning2014.
Emerging and Adjunctive Therapies for Influenza
Beyond traditional antivirals, new treatment approaches are under investigation. Monoclonal antibodies targeting the hemagglutinin (HA) stalk of the influenza virus have demonstrated the ability to neutralize a broad range of influenza A and B viruses and have been shown to be safe and effective in reducing symptoms in early clinical trials Sedeyn2019Koszalka2022. Other novel therapies, such as host-targeted drugs and nanotechnology-based treatments, are also being developed to address the limitations of current antivirals and to provide additional options in the face of emerging resistant strains Koszalka2022Singh2023Wang2022.
Special Considerations and Guidelines for Influenza Treatment
Current guidelines recommend early antiviral treatment for individuals with suspected or confirmed influenza who are severely ill, hospitalized, or at higher risk for complications, such as pregnant women, young children, the elderly, and those with chronic health conditions. Antiviral treatment may also be considered for otherwise healthy outpatients if it can be started within 48 hours of symptom onset Falagas2010Palomba2021Fiore2011. The choice of antiviral should be guided by local surveillance data and the circulating virus strains, as resistance patterns can vary Palomba2021Fiore2011.
Conclusion
Treatment options for influenza continue to evolve, with neuraminidase inhibitors remaining the standard of care and newer drugs like baloxavir marboxil and favipiravir offering additional choices. Combination therapies and monoclonal antibodies represent promising advances, especially for severe or resistant cases. Early initiation of antiviral therapy is crucial for optimal outcomes, and ongoing research is needed to address drug resistance and improve treatment strategies for all patient populations Falagas2010Sedeyn2019Koszalka2022+7 MORE.
Sources and full results
Most relevant research papers on this topic